Carlos V. Paya, MD, PhD, has served as a member of our board of directors since March 2017 and as board chair since May 2020. Dr. Paya brings to the Board over 19 years of senior executive experience in the large, mid-cap, and small-cap biopharmaceutical industries, combined with a prolific scientific background and a track record of leading high-impact innovation. Dr. Paya previously served as President, Chief Executive Officer, and a board member of Immune Design Corp., a clinical-stage immunotherapy company focused on oncology, from May 2011 until its acquisition by Merck & Co., Inc. in April 2019. He previously served as President of Elan Corporation, a pharmaceutical corporation later acquired by Perrigo Company, from 2008 to 2011. Before joining Elan Corporation, Dr. Paya was at Eli Lilly & Company from 2001 to 2008 as Vice President of Lilly Research Laboratories. From 1991 to 2001, Dr. Paya was Professor of Medicine, Immunology, and Pathology and Vice Dean of the Clinical Investigation Program at the Mayo Clinic in Rochester, Minnesota. Dr. Paya currently also serves on the board of directors of Mallinckrodt plc. He received his MD and PhD degrees from the University of Madrid and underwent postdoctoral training at the Institute Pasteur in Paris.